Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
04:30:00 08/09/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 5,760.00 JPY | 0.00% |
|
-0.09% | +19.13% |
| 08/09 | Pharvaris' genetic disorder drug meets main goal in late-stage trial | RE |
| 04/09 | After obesity, pharma seeks its next mega-blockbuster in sleep |  |
| Market Cap | 9,197B 59.88B 51.51B 48.46B 44.24B 82.5B 5,675B 82.98B 569B 221B 2,900B 225B 220B | P/E 2027 * |
45.6x | P/E 2028 * | 29x |
|---|---|---|---|---|---|
| Enterprise Value | 13,104B 85.32B 73.39B 69.04B 63.03B 118B 8,085B 118B 811B 315B 4,132B 320B 313B | EV / Sales 2027 * |
2.79x | EV / Sales 2028 * | 2.7x |
| Free-Float |
99.26% | Yield 2027 * |
3.55% | Yield 2028 * | 3.62% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4502 | Delayed | |
Tradegate
| TKD | Real-time | |
|
OTC Markets
| TKPHF | Delayed | |
|
Boerse Muenchen
| TKD | Real-time | |
|
Deutsche Boerse AG
| TKD | Delayed | |
|
Börse Stuttgart
| TKD | Delayed | |
|
Wiener Boerse
| TKD | End-of-day quote |
Last Transcript : Takeda Pharmaceutical Company Limited
| 1 week | -0.09% | ||
| Current month | -0.09% | ||
| 1 month | +3.97% | ||
| 3 months | +16.93% | ||
| 6 months | +1.28% | ||
| Current year | +19.13% |
| 1 week | 5,647 |  | 5,917 |
| 1 month | 5,482 | | 5,917 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 2/9/26 | Sell | Chief Technology Officer | -116,191 | 0.0073% | ||
| 19/8/26 | Sell | Chief Technology Officer | -19,651 | 0.0012% | ||
| 18/8/26 | Sell | Head of Human Resources | -12,980 | 0.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -0.09% | +25.93% | +27.26% | 59.8B | |
| -2.21% | -2.84% | +54.55% | +96.07% | 1,024B | |
| -2.22% | +1.23% | +50.83% | +68.17% | 663B | |
| -2.99% | -2.98% | +17.04% | +67.07% | 453B | |
| -0.88% | -0.65% | +27.83% | +36.57% | 349B | |
| -10.89% | -9.30% | +7.52% | +26.14% | 295B | |
| -1.38% | -0.79% | -1.77% | +9.72% | 253B | |
| -10.08% | -8.54% | +38.62% | +54.55% | 236B | |
| -2.32% | -0.14% | -16.57% | -56.82% | 206B | |
| -2.88% | +0.21% | +27.46% | +98.32% | 187B | |
| Average | -1.29% | +1.07% | +23.14% | +42.70% | 372.71B | |
| Weighted average by Cap. | -0.82% | +0.52% | +32.52% | +58.55% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,701B 30.61B 26.33B 24.77B 22.61B 42.17B 2,900B 42.41B 291B 113B 1,482B 115B 112B | 4,781B 31.13B 26.78B 25.19B 23B 42.89B 2,950B 43.14B 296B 115B 1,508B 117B 114B |
| Net income | 196B 1.28B 1.1B 1.04B 945M 1.76B 121B 1.77B 12.16B 4.73B 61.97B 4.8B 4.69B | 322B 2.1B 1.81B 1.7B 1.55B 2.89B 199B 2.91B 19.95B 7.76B 102B 7.88B 7.7B |
| Net Debt | 3,907B 25.44B 21.88B 20.58B 18.79B 35.04B 2,410B 35.24B 242B 93.99B 1,232B 95.43B 93.34B | 3,702B 24.1B 20.74B 19.51B 17.81B 33.21B 2,284B 33.4B 229B 89.07B 1,168B 90.44B 88.46B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/09/26 | JPY 5,760.00 | -0.29% | 2,467,300 |
| 07/09/26 | JPY 5,777.00 | +0.42% | 2,396,900 |
| 04/09/26 | JPY 5,753.00 | -2.62% | 5,384,700 |
| 03/09/26 | JPY 5,908.00 | +1.44% | 3,253,000 |
| 02/09/26 | JPY 5,824.00 | -0.36% | 3,692,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
